Literature DB >> 8310310

Chemotherapy for cervix cancer.

G A Omura1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8310310

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  2 in total

1.  A randomized phase II evaluation of bryostatin-1 (NSC #339555) in persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study.

Authors:  Deborah K Armstrong; John A Blessing; Janet Rader; Joel I Sorosky
Journal:  Invest New Drugs       Date:  2003-11       Impact factor: 3.850

2.  Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182-185.

Authors:  R Buckstein; R M Meyer; L Seymour; J Biagi; H Mackay; S Laurie; E Eisenhauer
Journal:  Curr Oncol       Date:  2007-08       Impact factor: 3.677
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.